Evidence implicating MIAT in cancer is now emerging and MIAT is selectively up-regulated in neuroendocrine prostate cancer [15] and in primary leukemic cells from patients with aggressive forms of CLL [16]. Here, MIAT is linked to B-cell chronic lymphocytic leukemia.